BRAF and melanoma: subsequently evaluated use of BRAF kinase inhibitors in conjunction with SRS for patients with melanoma brain metastases and found that patients with BRAF mutations treated with BRAF inhibitors had improved median survival times from diagnosis, and after SRS, of 23 months and 13 months (p < 0.01), respectively (65).